Zyrtec Dissolve Tabs lifts J&J's OTC sales in US

15 April 2014 - Deborah Wilkes

Archived

Johnson & Johnson said "strong sales" of Zyrtec, including initial stocking of the new Dissolve Tabs line extension, had helped push up its OTC sales in the US by 3.4% to US$366 million in the first quarter of 2014.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: